Dimos D Mitsikostas, Christina Deligianni, Artemis Mavridi, Victor Gkotzamanis, Theodoros Mavridis
{"title":"Steps to manage treatment-refractory migraine in adults.","authors":"Dimos D Mitsikostas, Christina Deligianni, Artemis Mavridi, Victor Gkotzamanis, Theodoros Mavridis","doi":"10.1080/14737175.2025.2555305","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Refractory migraine (RM) is characterized by a lack of response to both migraine-specific and repurposed treatments, significantly impairing quality of life. Risk factors for RM include, among others, overuse of symptomatic medications, nonadherence to treatment and comorbid conditions that limit the use of anti-migraine medications.</p><p><strong>Areas covered: </strong>This critical perspective addresses the diagnosis and management of patients with RM. It also highlights the best practices tailored to this complex condition, serving as a valuable tool for physicians.</p><p><strong>Expert opinion: </strong>Management demands specialized, holistic approach that considers patient preferences and may deviate from conventional evidence-based practices. Diagnosis requires thorough evaluation to exclude conditions like cluster headaches or trigeminal neuralgias. Treatment integrates symptomatic, interim, and prophylactic strategies. Symptomatic options include triptans, ditans, and gepants, often combined with NSAIDs or antiemetics, but gepants are first-line option because of their low risk for medication overuse headache. Interim treatments, intended to bridge to prophylactic therapy, might involve steroids or long acting triptans. Prophylactic treatments favor migraine-specific medications due to their superior tolerability and effectiveness. Non-pharmacological approaches are also encouraged while continuous monitoring and reassessment after initial treatments are essential, recognizing that RM may recur after a temporary improvement phase.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-15"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2025.2555305","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Refractory migraine (RM) is characterized by a lack of response to both migraine-specific and repurposed treatments, significantly impairing quality of life. Risk factors for RM include, among others, overuse of symptomatic medications, nonadherence to treatment and comorbid conditions that limit the use of anti-migraine medications.
Areas covered: This critical perspective addresses the diagnosis and management of patients with RM. It also highlights the best practices tailored to this complex condition, serving as a valuable tool for physicians.
Expert opinion: Management demands specialized, holistic approach that considers patient preferences and may deviate from conventional evidence-based practices. Diagnosis requires thorough evaluation to exclude conditions like cluster headaches or trigeminal neuralgias. Treatment integrates symptomatic, interim, and prophylactic strategies. Symptomatic options include triptans, ditans, and gepants, often combined with NSAIDs or antiemetics, but gepants are first-line option because of their low risk for medication overuse headache. Interim treatments, intended to bridge to prophylactic therapy, might involve steroids or long acting triptans. Prophylactic treatments favor migraine-specific medications due to their superior tolerability and effectiveness. Non-pharmacological approaches are also encouraged while continuous monitoring and reassessment after initial treatments are essential, recognizing that RM may recur after a temporary improvement phase.
期刊介绍:
Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points